Autoinjectors Market

Eli Lilly (US) and Mylan (US) are the Major Players in the Autoinjectors Market

The global autoinjectors market is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018 at a CAGR of 24.2%. The autoinjectors market is rapidly emerging with many regional as well as international companies. In 2017, Abbvie (US), Amgen (US), Teva (Israel), Biogen (US), Eli Lilly (US), and Mylan (US) held a share of approximately 70% to 75% of the autoinjectors market, whereas SHL Group (Taiwan), Ypsomed (Switzerland), Becton, Dickinson and Company (US), Owen Mumford (UK), and Haselmeier (Switzerland) were the top five OEM companies in the global autoinjectors market.

Abbvie (US) dominated the autoinjectors market for rheumatoid arthritis in 2017. The company offers autoinjector devices for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and psoriatic arthritis. The company has its distribution and production facilities in more than 75 countries. The company primarily focuses on expanding its geographic reach to maintain its leadership position in the market. For instance, in 2017, the company established a new biologics manufacturing facility in Tuas, (Singapore) in order to meet the increasing demand for biologics for various autoimmune and chronic diseases. The company continuously strives to strengthen its market position by focusing on expanding its product portfolio through product launches and agreements. For instance, in June 2018, the company launched a new autoinjector for Humira delivery. Similarly, in April 2018, the company signed a licensing agreement with Samsung Bioepis, to promote Humira biosimilar “Imraldi” in Japan.

To know about the assumptions considered for the study download the pdf brochure

Teva (Israel) is one of the leading players in the autoinjectors market. The company offers autoinjectors for the treatment of rheumatoid arthritis, anemia (in cancer patients), and hyperlipidemia. The company manufactures and distributes generic and specialty products in more than 70 countries around the world and operates 62 finished dosage and packaging pharmaceutical plants in 33 countries. The company’s manufacturing sites are located in Israel, Germany, Hungary, Croatia, Bulgaria, India, Spain, and the Czech Republic. In order to strengthen its position in the market, the company significantly invests in R&D activities. In 2017, the company invested USD 884.0 million in R&D activities to innovate and launch new products in the market.

Eli Lilly (US) is one of the major players in the autoinjectors market for diabetes. The company provides disposable autoinjectors for the treatment of type 2 diabetes mellitus and psoriasis. The company sells its products in approximately 125 countries. It focuses on R&D investments for the development of technically advanced products. Its R&D expenditure during fiscal years 2017, 2016, and 2015 were USD 5.28 billion, USD 5.24 billion, and USD 4.80 billion, respectively. In line with this strategy, in 2015, Eli Lilly also established an innovation center in Cambridge, Massachusetts (US) with a focus on drug delivery and device innovation.

Mylan (US) is a key player in the autoinjectors market for anaphylaxis. The company offers disposable epinephrine autoinjectors for the treatment of anaphylaxis under the brand name EpiPen. The company has a robust worldwide commercial presence, including the leading position in the US, Australia, France, as well as other markets around the world. The company has a portfolio of more than 7,500 marketed generic, branded, and OTC products. The company owns 12 manufacturing and distribution facilities in the US. Furthermore, the company has its production and distribution facilities in 11 countries including key facilities in India, Australia, Japan, Ireland, Hungary, and France.

Some of the other players competing in this market are Amgen (US), Biogen (US), BMS (US), Merck (Germany), AstraZeneca (UK), GSK (UK), Novartis (Switzerland), and J&J (US).

Related Reports:

Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Report Code
MD 6494
RI Published ON
8/1/2018
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Autoinjectors Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved